Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers

Exclusion Criteria

• •Pregnant women, nursing mothers or women of childbearing potential
• •Clinically significant abnormalities in medical history or physical examination
• •Clinically significant abnormalities in laboratory examination (including ALT \> ULN, AST \> ULN, bilirubin \> ULN, creatinine \> ULN, urine protein positive by urine dipstick, platelets \< lower limit of normal and any other clinically significant laboratory findings)
• •Estimated GFR \< 60 mL/min per 1.73m²
• •History of clinically significant abnormalities in coagulation parameters
• •Positive test result for HIV, hepatitis B virus, and/or hepatitis C virus
• •Active infection requiring antiviral or antimicrobial therapy
• •Subjects on chronic or acute prescription medication may be permitted after discussion with the Isis Medical Monitor
• •Malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for \> 1 year)
• •Any other concurrent condition which, in the opinion of the Investigator, would preclude participation in this study or interfere with compliance
• •Past and present history of alcohol or drug abuse (defined as \> 3 units daily)
• •Undergoing or have undergone treatment with another investigational drug, biologic agent or device within 90 days prior to Screening
• •Blood donation within three months of Screening